ImmunityBio, Inc.
IBRX Healthcare Biotechnology
ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024. In the quarter to June 2026, revenue grew 93.9%, EPS fell 120.0%, free cash flow grew 13.4% and total debt rose 57.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow IBRX
ImmunityBio, Inc. (IBRX) EV/Sales
As of 16 October 2026, ImmunityBio, Inc. (IBRX) trades at a EV/Sales of 63.6×. Over the past ten years it has ranged from −267× (July 2015) to 26,606× (February 2021); the current reading is higher than 13% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 22.4× | (87.19%) |
| FY2024 | 175× | (96.95%) |
| FY2023 | 5,727× | (44.43%) |
| FY2022 | 10,306× | 262.15% |
| FY2021 | 2,846× | (66.84%) |
| FY2020 | 8,581× | 1,298.04% |
| FY2019 | 614× | (25.01%) |
| FY2018 | 818× | (84.74%) |
| FY2017 | 5,365× | (17.92%) |
| FY2016 | 6,536× | 63.20% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 60.9× | (0.80%) |
| Mar 2026 | 61.4× | 174.11% |
| Dec 2025 | 22.4× | (39.44%) |
| Sep 2025 | 37.0× | (33.86%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PCVX Vaxcyte, Inc. compare | n/m |
| BMRN BioMarin Pharmaceutical Inc. compare | 4.1× |
| TECH Bio-Techne Corp compare | 9.3× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 9.8× |
| CORT Corcept Therapeutics Incorporated compare | 13.6× |
| KRYS Krystal Biotech, Inc. compare | 19.3× |
| IBRX ImmunityBio, Inc. | 63.6× |
| KYMR Kymera Therapeutics, Inc. compare | 91.4× |
| SMMT Summit Therapeutics PLC compare | 15,310× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)